The efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin was studied in Pioneer 8 Trial, by Zinman et al., where T2DM patients were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) for 52 weeks [21]. This evidence concerns the gene INS and type 2 diabetes mellitus.